Friday, July 10, 2026

pharma · Clear Cell Renal Cell Carcinoma · Cushing s Syndrome

Peking University Biologics

Peking University Third is a pharma organization headquartered in CN. Primary therapeutic focus areas include Clear Cell Renal Cell Carcinoma, Cushing s Syndrome, Esophageal Cancer, Prostate Cancer, Aged. NovaPharmaNews

仙霞路, 319号, 上海市, 长宁区, CN HQ
2018 Founded
8 Employees
NMPA registrant Type
Company details
Status
Public
HQ
仙霞路, 319号, 上海市, 长宁区, CN
Founded
2018
Employees
8
Programs
15
Drugs
25
Patents
0
Clinical program

68Ga-NY104 PET/CT

Phase 2 · other · Clear Cell Renal Cell Carcinoma

68Ga-NY104 PET/CT for Clear Cell Renal Cell Carcinoma is a Phase 2 program (other) at Peking University Third Hospital with 1 ClinicalTrials.gov record(s).

Internal code NYCRPS

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Peking University Third Hospital
Phase
Phase 2
Modality
other
Indication
Clear Cell Renal Cell Carcinoma
Status
active
Trials
1

Clinical trials